YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

✍ Scribed by Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang Lü; Yongping Xu; Jin Li; Liguang Lou

• Book ID: 108587076
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 527 KB
• Volume: 102
• Category: Article
• ISSN: 1347-9032
• DOI: 10.1111/j.1349-7006.2011.01939.x

✦ Synopsis

Angiogenesis is an important process in cell development, especially in cancer. Vascular endothelial growth factor (VEGF) signaling is an important regulator of angiogenesis. Several therapies that act against VEGF signal transduction have been developed, including YN968D1, which is a potent inhibitor of the VEGF signaling pathway. This study investigated the antitumor activity of YN968D1 (apatinib mesylate) in vitro and in vivo. YN968D1 potently suppressed the kinase activities of VEGFR‐2, c‐kit and c‐src, and inhibited cellular phosphorylation of VEGFR‐2, c‐kit and PDGFRβ. YN968D1 effectively inhibited proliferation, migration and tube formation of human umbilical vein endothelial cells induced by FBS, and blocked the budding of rat aortic ring. In vivo, YN968D1 alone and in combination with chemotherapeutic agents effectively inhibited the growth of several established human tumor xenograft models with little toxicity. A phase I study of YN968D1 has shown encouraging antitumor activity and a manageable toxicity profile. These findings suggest that YN968D1 has promise as an antitumor drug and might have clinical benefits. (Cancer Sci 2011; 102: 1374–1380)